Evidence map›Paper›PMID 32601337›Full record

Trial reportNature medicine2020

Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents.

Carsten Riether, Thomas Pabst, Sabine Höpner, Ulrike Bacher, Magdalena Hinterbrandner, Yara Banz, Rouven Müller, Markus G Manz, Walid H Gharib, David Francisco and 11 more

Abstract readClinical Trial, Phase IClinical Trial, Phase II
PubMed Publisher
In one paragraph

Trial report in Nature medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 149 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
149citing papers in PubMed, 1 pooled it
14.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

149 citing papers in PubMed, 1 synthesis or guideline pooled it, 204 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. TheHematology reports · 2026
    Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review

89 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 3 institutions in 2 countries.

Carsten RietherDepartment of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. carsten.riether@insel.ch.ORCID http://orcid.org/0000-0001-7512-513X
Thomas PabstDepartment of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Sabine HöpnerDepartment of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Ulrike BacherDepartment of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Magdalena HinterbrandnerDepartment of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Yara BanzInstitute of Pathology, University of Bern, Bern, Switzerland.
Rouven MüllerDepartment of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
Markus G ManzDepartment of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.ORCID http://orcid.org/0000-0002-4676-7931
Walid H GharibInterfaculty Bioinformatics Unit and SIB Swiss Institute of Bioinformatics, University of Bern, Bern, Switzerland.
David FranciscoInterfaculty Bioinformatics Unit and SIB Swiss Institute of Bioinformatics, University of Bern, Bern, Switzerland.
Remy BruggmannInterfaculty Bioinformatics Unit and SIB Swiss Institute of Bioinformatics, University of Bern, Bern, Switzerland.
Luc van Rompaeyargenx BVBA, Zwijnaarde, Belgium.
Mahan Moshirargenx BVBA, Zwijnaarde, Belgium.
Tim Delahayeargenx BVBA, Zwijnaarde, Belgium.
Domenica Gandiniargenx BVBA, Zwijnaarde, Belgium.
Ellen Erzeelargenx BVBA, Zwijnaarde, Belgium.
Anna Hultbergargenx BVBA, Zwijnaarde, Belgium.
Samson Fungargenx BVBA, Zwijnaarde, Belgium.
Hans de Haardargenx BVBA, Zwijnaarde, Belgium.
Nicolas Leupinargenx BVBA, Zwijnaarde, Belgium.
Adrian F OchsenbeinDepartment of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. adrian.ochsenbein@insel.ch.ORCID http://orcid.org/0000-0003-1773-5436
University of Bern · CHAblynx (Belgium) · BEUniversity of Zurich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute myeloid leukemia (AML) is driven by leukemia stem cells (LSCs) that resist conventional chemotherapy and are the major cause of relapse

Indexed as

Antibodies, MonoclonalAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsApoptosisAzacitidineCD27 LigandDNA MethylationHumansLeukemia, Myeloid, AcuteNeoplastic Stem CellsTreatment OutcomeTumor Necrosis Factor Receptor Superfamily, Member 7Antibodies, MonoclonalAntineoplastic AgentsAzacitidineCD27 LigandCD70 protein, humanTumor Necrosis Factor Receptor Superfamily, Member 7

Identifiers

PMID32601337
OpenAlexW3037802405

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.